(Q46177233)

20 December 2017

title

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients (English)

1 reference

20 December 2017

6

Sophie Postel-Vinay

0 references

Johann de Bono

8

object named as

Johann de Bono

1 reference

20 December 2017

author name string

Robin L Jones

1

1 reference

20 December 2017

David Olmos

2

1 reference

20 December 2017

Khin Thway

3

1 reference

20 December 2017

Cyril Fisher

4

1 reference

20 December 2017

Nina Tunariu

5

1 reference

20 December 2017

Sophie Postel-Vinay

6

1 reference

20 December 2017

Michelle Scurr

7

1 reference

20 December 2017

Stan B Kaye

9

1 reference

20 December 2017

Ian R Judson

10

1 reference

20 December 2017

publication date

11 November 2010

1 reference

20 December 2017

Cancer Chemotherapy and Pharmacology

published in

1 reference

20 December 2017

volume

68

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

423-429

1 reference

20 December 2017

Opportunities for improving the therapeutic ratio for patients with sarcoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

Soft-tissue sarcomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

Role of chemotherapy in the management of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1484-9

10.1007/S00280-010-1484-9

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017